ESSA Pharma (US:EPIX) Prnewswire·2025-03-10 09:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from December 12, 2023, to October 31, 2024 [2]. - Allegations include that the defendants made materially false statements about masofaniten's efficacy, claiming it had benefits over enzalutamide alone, which was not supported by evidence [2]. - The M-E Combination Study was unlikely to meet its primary endpoint, contradicting the defendants' claims about masofaniten's prospects [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by March 25, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4]. - The firm seeks recovery for investors who suffered losses due to misleading statements that inflated stock prices [4].